OvaScience Reports Third Quarter 2014 Financial Results
- Company Ahead of Schedule in Achieving Key 2014 AUGMENTSM Treatment Goal -
“The interest in our AUGMENT treatment from global fertility specialists
has exceeded our expectations, resulting in
Third Quarter and Recent Highlights
Achieved 2014 Goal for AUGMENTSM Treatment
Company is ahead of schedule and has already exceeded the targeted 40-60 AUGMENT treatment cycles that were anticipated this year. The AUGMENT treatment is available in certain in vitro fertilization (IVF) clinics in three international regions, and
OvaScienceremains on track to launch the treatment in a fourth international region this year. The AUGMENT treatment is specifically designed to improve egg health by using mitochondria from a patient’s own egg precursor (EggPCSM) cells during IVF. The AUGMENT treatment is not available in the United States.
Advanced Studies of OvaPrimeSM Treatment
to Support Planned Launch in 2015
Continued to progress studies of the OvaPrime treatment, with results expected by the end of 2014 to support a planned launch in certain IVF clinics in select international regions in the second half of 2015. The OvaPrime treatment is a potential new fertility treatment that uses EggPC cells to expand a woman’s egg reserve for IVF.
Human Proof-of-Concept Research
Advanced preclinical human proof-of-concept studies of the OvaTure treatment, with results expected by the end of the year. The OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without the need for hormone injections.
Hosted Symposium for Global Reproductive Endocrinologists and other
Fertility Specialistsat Annual Fertility Meeting
Participated in the American Society for Reproductive Medicine (ASRM) Annual Meeting and held a symposium featuring presentations by experts from the
National Institutes of Health, National Foundation for Fertility Researchand Taipei Medical University.
Launched New Corporate Website
OvaSciencecorporate website to provide additional fertility education resources. For more information, visit www.ovascience.com.
Third Quarter 2014 Financial Results
Net loss for the three months ended
September 30, 2014was $12.9 million, or ($0.54)per share, as compared to net loss of $6.9 million, or ($0.40)per share, for the three months ended September 30, 2013. The increase is primarily attributable to planned higher personnel costs, stock-based compensation expense, additional research and development expense related to the proof-of-concept studies for the OvaPrime and OvaTure treatments, and costs associated with the launch of the AUGMENT treatment in select international regions. Launch costs include legal and consulting services and establishment of lab-based operations expected to be utilized in future treatment launches.
Research and development expense for the three months ended
September 30, 2014was $5.3 million, compared to $3.2 millionfor the same period in 2013. The increase is primarily attributable to increased stock-based compensation expense, due in large part to mark-to-market accounting of certain Founders’ stock, and additional research and development costs associated with lab operations and other research collaborations to advance the development of the OvaPrime and OvaTure treatments.
Selling, general and administrative expense for the three months ended
September 30, 2014was $7.1 million, as compared to $3.7 millionfor the same period in 2013. The increase is primarily attributable to higher personnel costs, including stock-based compensation, and other legal and consulting services.
Upcoming Events and Presentations
Cures Conference, November 16-18in New York, NY
Fortune Most Powerful Women Next Gen Summit,
December 2-3in San Francisco, CA
Oppenheimer Healthcare Conference, December 10-12in New York, NY
OvaScience Investor Day,
December 17in New York, NY
Forward-Looking Statements – This press release includes forward-looking statements about the Company’s plans (i) to expand the AUGMENT treatment to more international clinics and to launch the treatment in a fourth international region in 2014, (ii) to have results of proof-of-concept studies of the OvaPrime treatment by the end of 2014 and to launch the OvaPrime treatment in the second half of 2015, (iii) to have results of preclinical human proof-of-concept studies for the OvaTure treatment at the end of 2014, and (iv) plans and treatment possibilities for the AUGMENT treatment and its two potential fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with or plan to work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we plan to introduce the AUGMENT treatment and OvaPrime treatment; our ability to expand our current and potential treatments into additional international markets; the science underlying our treatment and potential treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval as necessary for our fertility treatment launched in certain IVF clinics in select international regions and our potential fertility treatments; our ability to develop our potential fertility treatments, including the AUGMENT treatment, OvaPrime treatment and OvaTure treatment, on the timelines we expect, if at all; our ability to commercialize our treatments, including the AUGMENT treatment and OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
– Financial Tables to Follow –
|Condensed Consolidated Statements of Operations|
|(In thousands, except per share data)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Research and development||$||5,325||$||3,262||$||14,511||$||8,518|
Selling, general and
|Total operating expenses||12,399||6,925||29,644||18,121|
|Loss from operations||(12,399||)||(6,925||)||(29,644||)||(18,121||)|
|Interest (expense) / income, net||(25||)||34||(109||)||77|
|Other income / (expense), net||24||-||38||-|
|Loss from equity method investment||(523||)||-||(915||)||-|
|Net loss per share—basic and diluted||$ (0.54||)||$ (0.40||)||$ (1.38||)||$ (1.14||)|
Weighted average number of
shares used in net loss per
share—basic and diluted
|Condensed Consolidated Balance Sheets|
|As of September 30,||As of December 31,|
|Cash and cash equivalents||$||12,125||$||18,078|
|Prepaid expenses and other current assets||1,448||650|
|Total current assets||73,614||45,077|
|Property and equipment, net||3,103||880|
|Investment in joint venture||585||1,500|
|Liabilities and stockholders’ equity|
|Total current liabilities||8,803||5,774|
|Other non-current liabilities||71||70|
|Total stockholders’ equity||68,625||41,701|
|Total liabilities and stockholders’ equity||$||77,499||$||47,545|
Theresa McNeely, 617-299-7356
EVP, Strategic Corporate Communications
Cara Petralia, 617-714-9638
Director, Corporate Communications